More Evidence Links Celebrex to Heart Problems
Posted on: Tuesday, 1 February 2005, 06:00 CST
A consumer advocate Monday accused Pfizer, the maker of Celebrex, of hiding the results of a study in which patients who took the drug were 3 times more likely to have a stroke, heart attack or other serious cardiovascular problem than those on a placebo.
Sidney Wolfe of Public Citizen's Health Research Group had petitioned the Food and Drug Administration on Jan. 24 to ban Celebrex and Bextra, the only COX-2 inhibitor pain relievers still sold in the USA. Meanwhile, Kaiser Permanente has decided to stop dispensing Bextra at its California pharmacies because of cardiovascular safety concerns.
Merck withdrew Vioxx, its COX-2 inhibitor, Sept. 30 after a study found a higher risk of heart attacks and stroke in volunteers who took the drug compared with those on a placebo. Although some scientists believe all COX-2 inhibitors have a similar effect, Pfizer ran full-page ads in USA TODAY and elsewhere assuring patients that Celebrex was safe.
In a follow-up letter Monday, Wolfe told acting FDA commissioner Lester Crawford that he had just discovered an unfavorable Celebrex study, apparently posted the day he submitted his petition, on a clinical trials Web site run by the Pharmaceutical Research and Manufacturers Association, or PhRMA.
In a statement Monday, Pfizer said it did not hide the study. It said it was presented at a scientific meeting in 2000 and given to the FDA in June 2001. The study, which never ran in a medical journal, randomly assigned 285 Alzheimer's patients to Celebrex and 140 to a placebo. When major cardiovascular problems were combined, those on Celebrex had a significantly higher risk.
On the PhRMA Web site and in its statement, Pfizer explained that the Celebrex patients were more likely to have cardiovascular disease risk factors than those on a placebo. But Wolfe says he's skeptical, because the point of randomized trials is to eliminate patient differences that could affect the results.
Recent studies involving Celebrex have yielded conflicting results. An FDA-sponsored study posted in January on The Lancet Web site, as well as a Canadian study posted online Monday by the Annals of Internal Medicine, found a higher risk of cardiovascular problems in patients whose doctors prescribed Vioxx, but not in those getting Celebrex.
Also in December, the National Institutes of Health halted two studies in which participants were randomly assigned to take Celebrex or a placebo or, in one of the two, Aleve, the non-prescription brand of naproxen. One linked Celebrex to heart attacks and strokes; the other linked Aleve, not Celebrex.
Source: USA TODAY
Related Articles
- Statins May Prevent Blood Clots In Patients With Cardiovascular Disease
- 8 Ounces a Day of POM Wonderful 100% Pomegranate Juice May Slow Progression of Carotid Intima-Media Thickness (CIMT) in Patients with Elevated Cardiovascular Disease Risk Factors, Study Finds
- Atrial Fibrillation Found to Be Common in Patients With Atherothrombosis, Increases Risk of Cardiovascular Death, Heart Attack and Stroke
- International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed Are at Risk for VTE and Many Do Not Receive Recommended VTE Prophylaxis
- Study Links Estrogen, Breast Cancer Risk
- Study Shows Potential of Pfizer's Lipitor in MS
- Covalent Group, Inc. Signs $2.2 Million Contract With New Sponsor to Conduct Clinical Trial in Patients With Cardiovascular Disease
- FDA Approves Expansion of Angiomax(R) (Bivalirudin) Label to Include Patients With or at Risk of HIT/HITTS Undergoing PCI; HIT/HITTS Places Patients at Higher Risk of Life-Threatening Complications
- Database Studies May Not Accurately Estimate Risk of MI in Naproxen, Ibuprofen Users
- New Study Results Reaffirms Diachrome(R) Significantly Improves Cardiovascular Disease Risk Factors in People With Type 2 Diabetes
 |
 |
User Comments (0)
RSS Feeds